English (UK)
中文版MID LABS 
MID Labs continues to innovate with the MID Labs branded product line which is supplied to more than 30 countries around the world. These products set the standard for precision, performance, and quality.
Dr. Kai Chen
CEOMIMETAS Organ on a chip company 
MIMETAS BV develops organ-on-a-chip tissue models for evaluating drugs, chemicals and food components. Its unique microfluidic technology, designated OrganoPlates®, enables testing of compounds in high-throughput on miniaturized organ models. These models show better predictivity as compared to laboratory animals and conventional cell culture models. The OrganoPlate® platform supports 3D cell culture under continuous perfusion and membrane-free co-culture, including epithelial and endothelial boundary tissues. MIMETAS offers OrganoPlates®, develops and validates customised disease, toxicology and transport models and will ultimately make her technology available for personalised therapy selection.
Mr. Luc Zhang
VP Great ChinaMira Life Science Ventures
Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.
In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.
Mr. Mel Rothberg
ChairmanMSQ Ventures
Mr. Estigarribia Marc
MDMyriad Genetics
Myriad Genetics is a technology-enabled molecular diagnostics company, with worldwide presence. Our genetic tests play in Oncology, Women's Health (e.g., prenatal), and Mental Health areas.
Jackie Z
Business Development Lead
NeuroZone 
Neuro-Zone, since 13 years, supports drug discovery, drug repurposing and research projects in the fields of inflammation and age-related pathologies.
In particular, we have developed pathology-specific platforms to generate rapid and informative data on efficacy, toxicity, metabolism and mechanism of action, supported by proprietary technologies such as MicroTISSUE (dissecting microenvironment-cell interaction in complex inflammatory scenarios) or MITOS (a comprehensive analytical platform for quantitative analysis of mitochondrial function ).
Our approach enables effective selection and ranking of the most promising candidates per indication.
Moreover, we profile candidates at different level of complexity starting from:
a) pharmacology profiling (GPCR; Ion Channel receptors)
b) identification of biochemical pathways responsible for therapeutic efficacy (transcriptomics)
c) disease modified barrier permeability (BBB and endothelial)
Fabio Bianco
PresidentNew.Fa.Dem. Srl
New.Fa.Dem, a manufacturing company based in Italy and is authorized by Italian Agency of Drugs.
Conducts activities like R&D, Manufacturing, Distribution of ethical drugs, medical devices and cosmetics with own brand or private labeling.
Manufacturing of Creams, Gels, liquid, powder and suppositories.
Three important certifications:
• ISO 9001: 2015 for compliance with international quality management standards;
• ISO 13485: 2016 for congruence with the legislation relating to the quality of medical devices;
• GMP COMPLIANCE for the possession of authorizations and licenses for the production of pharmaceutical products.
Possibility of manufacturing medical devices and cosmetics of the same form in the facility in the near future.
Successfully present in Europe, Middle East and North Africa.
ISO Certifications for compliance of international standards of Quality Management and rules on the quality of Medical Devices.
Maria Goncharova
BD DirectorNovelstar Pharmaceuticals Inc.
Dr. Shao Fu
VPNovodiax
Novodiax pioneered a 10-minute ihcDirectTM IHC detection for frozen section technology, which significantly saves time and reduces reagent consumption and costs with easy to use by reducing steps from traditional protocols. This innovated technology has removed many of the time constraining barriers that once prevented application of IHC stains in intraoperative diagnosis and Mohs surgery labs.
Novodiax also provides multiplex IHC detection which accelerates turnaround time, increases instrument productivity and reduces reagent consumption.
In summary Novodiax enjoys the following major strength
1- Novodiax currently offers a 10 min IHC product line that can be used for intraoperative evaluation of frozen tissues and for Rapid On-Site Evaluation (ROSE) of biopsy specimens.
2- Novodiax will launch in Q4 2020 an advanced automation system including a rapid compact IHC stainer and a superfast FFPE tissue pre-treatment device along with tens of ihcDirect® IHC reagents. This affordable system is a perfect solution for any situation where a rapid turnaround time is needed, such as, the rush cases using FFPE tissues in large medical centers. Our 10 min intraoperative and ROSE protocols will be available on the system too.
3- Novodiax products have already been optimized for Leica staining instruments and can be optimized for all automated staining platforms in the market.
4- The rapid turnaround time of Novodiax’s reagents and instruments offers a natural advantage for multiplex applications.
Responsive Web Design powered by 